“Hyperpolarized Carbon-13 Imaging of Metastatic Prostate Cancer”
A pilot study with a group of up to 10 men with CRPC about to embark on a 6-month course of treatment with radium 223. Study participants will undergo anatomical MR imaging combined with the new hyperpolarized MRI (1 hour exam) prior to treatment.
Hyperpolarized Pyruvate (13C)
MRI contrast agent
Hyperpolarized Carbon-13 Imaging of Metastatic Prostate Cancer